Your session is about to expire
← Back to Search
Probiotic Supplement for Heart Failure
Study Summary
This trial will study how a probiotic supplement affects exercise capacity, biomarkers, quality of life, and vascular function in people with HFrEF and inflammation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have severe heart problems caused by certain valve diseases.You have a gastrointestinal illness that affects how your body absorbs probiotics.You must be between 21 and 89 years old.You have chronic kidney disease with a very low eGFR level.You have heart failure symptoms and a specific level of heart function, as shown by a heart ultrasound.You have signs of widespread inflammation in your body when you are screened for the trial.You are currently taking or have taken steroids or anti-inflammatory treatments (except for certain types) in the past 14 days.Your blood doesn't have enough infection-fighting white blood cells.You have cancer other than non-melanoma skin cancer, localized prostate cancer, or localized breast cancer, and your doctor expects you to live less than one year.You have lung conditions like COPD, emphysema, or pulmonary fibrosis.You have been diagnosed with congestive heart failure and have a recent test showing that your heart is not pumping properly.You have been diagnosed with heart failure in the past six months, and tests show specific heart function issues.You have severe liver problems.You are expected to need heart surgery during the study.You are taking blood thinners like Coumadin or Warfarin.You are currently taking a Lactobacillus-based probiotic as an outpatient.You cannot walk on a treadmill or use a bicycle for exercise testing.You are allergic to the Lp299v probiotic supplement.
- Group 1: Lp299v
- Group 2: Placebo Control
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this trial accept volunteers outside of the 35-year age bracket?
"Due to the requirements of the research, enrolment for this study is limited to persons aged 21-89."
Am I eligible to participate in the research project?
"This study, which seeks to recruit 20 people in total, is open to those between 21 and 89 years old with a diagnosis of heart failure."
Are there any opportunities to take part in this investigation at the moment?
"Verified. Clinicaltrials.gov has this trial listed as actively enrolling patients, with the original posting being on February 20th of 2021 and an update occurring one day later."
How many subjects are enrolled in this scientific experiment?
"Affirmative. Clinicaltrials.gov denotates that this medical trial, first published on February 20th 2021 is still looking for participants. Only a total of 20 individuals are needed at one site to complete the study."
What are the projected effects of this trial?
"The main objective of this research, assessed over approximately 12 weeks, is to evaluate Brachial Artery Flow Mediated Dilation (FMD%). Additional quantitative parameters comprise Resting Shear Stress of the Brachial Artery indicative of vascular rigidity, velocity at rest corresponding to vascular firmness and alteration in serum Soluble Suppression Tumorigenesis (SST2) as a marker of cardiac fibrosis."
Share this study with friends
Copy Link
Messenger